Incretin effects on β-cell function, replication, and mass: the human perspective. - Wikidata - wikimedia - TriplyDB

Incretin effects on β-cell function, replication, and mass: the human perspective.

Incretin effects on β-cell function, replication, and mass: the human perspective.

http://www.wikidata.org/entity/Q39988564

about

Potential Bioactive Compounds from Seaweed for Diabetes Management Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes Concise review: pancreas regeneration: recent advances and perspectives Practical combination therapy based on pathophysiology of type 2 diabetes Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study.Human β-cell regeneration: progress, hurdles, and controversy.The potential role of incretin therapy in the hospital setting.Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives.Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes miR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker development The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.Longer-Term Physiological and Metabolic Effects of Gastric Bypass Surgery Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability.Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care.Making β cells from adult cells within the pancreas.At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.Sleeve gastrectomy, but not duodenojejunostomy, preserves total beta-cell mass in Goto-Kakizaki rats evaluated by three-dimensional optical projection tomography.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.Anti-diabetic potential of selected Malaysian seaweeds Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

P2860

Q26797339-7BBC6EA0-C8D4-4FF1-BA33-5ED2B79B724A Q26861768-712321DD-F70A-441B-98CD-B123DDBE838A Q27013646-59AB2DE5-9E2D-46DB-815C-E6B1A6DA22E6 Q28076530-25827A9F-F30E-4495-88C0-11539C1B02EC Q33551724-5E5F1751-DE47-4E6D-89DD-2721FBCDB8F4 Q33776142-4D65FB97-F198-4739-91C5-7D116AD06AF6 Q33792390-DD101A18-DC6E-440B-9A8C-7BB342F075C6 Q33844872-7CA02406-4380-44EF-8C55-84CFD1016FBB Q34344032-73A20B66-CA04-4D93-855A-A3529E2E04BA Q34498840-5E1E468E-0529-437E-8347-F2AB3FC9F00A Q34592864-6A382508-B5B5-4921-81EA-05CD1262F2AD Q35184904-68BBF3F9-54CF-4660-9762-5F10B2C360A4 Q35305506-3B1BA07B-E06A-45D2-836D-DFAC6B13ACA2 Q35994230-3AE65CAA-0EDF-4700-A767-8DA807EFC173 Q36072493-1FAF2F77-AFD2-49C4-BAF0-9203209464C8 Q36109279-B343E8AC-246F-4A9F-99B5-999EDA44EEB3 Q36182540-64E50405-A5A8-4180-8F89-E8C0D14507BF Q36567296-130B370F-4387-490C-B837-8D37CFFE19C0 Q36720596-811CD15E-EA02-413D-AE34-2DABAC038B8B Q36833164-576FF9F9-ACA8-4C23-8328-6A68F9600A36 Q37550281-7F71894C-8BEE-4A9D-A97E-2B446C9AD841 Q38020015-3ED4EDAD-DB97-420E-8843-444CAD11AA5B Q38068629-C3828A9E-0428-4A06-9195-51889A689B32 Q38127356-AF635EDD-DA63-49C2-85EE-CED95CFFAB86 Q38200704-82C5B5C1-0D9A-4DC4-87F9-3CA68F1D54FF Q38285665-06E0E312-8052-4B5B-87B9-6A0CB6D55CD0 Q38901991-6C7CDB07-BDE9-4538-9ED4-B23054B95FA4 Q38931845-A82262DD-EB52-4A61-B4C2-43804B334E80 Q39101720-9289DEBA-737D-49AF-8F83-7F5D3A8D210D Q39345729-F16779DB-59BB-458C-A8C2-0D2293AE9C1A Q40998901-EF783EC2-E987-49A5-A53F-0060B9106EBD Q42463784-9C5809FB-93E6-49BD-8BA3-FCD9D03FF4A7 Q42665424-B09FDB37-B8B1-498B-AA0E-4C711CC88584 Q51301524-99C6342B-A55F-45F0-9A3F-1F435F8D3BFE Q51301791-B28A6E8C-A673-4807-888E-595129BE30F7 Q54580077-B71DC022-FB1F-491B-86A0-F719F16FFDD9 Q56940876-46B160BE-F4F8-4017-A7CD-C75FF999B771 Q57591345-E33CD7A3-8424-4D14-AE67-9BA7CDC4284B

P2860

Incretin effects on β-cell function, replication, and mass: the human perspective.

http://www.wikidata.org/entity/Q39988564

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Incretin effects on β-cell function, replication, and mass: the human perspective.

@en

Incretin effects on β-cell function, replication, and mass: the human perspective.

@nl

type

label

Incretin effects on β-cell function, replication, and mass: the human perspective.

@en

Incretin effects on β-cell function, replication, and mass: the human perspective.

@nl

prefLabel

Incretin effects on β-cell function, replication, and mass: the human perspective.

@en

Incretin effects on β-cell function, replication, and mass: the human perspective.

@nl

P1433

Q39988564-3EA598F7-061B-48CA-9CED-70EB9D18DB42

P1476

Q39988564-378EBD3D-D6DC-4748-B394-85C8378AD87A

P2093

Q39988564-2AD56ED3-331A-4707-85EA-CBFDD9DF374D

P2860

Q39988564-03E92890-B6FC-497F-A5B1-1BA780C8F18B

Q39988564-0489E007-1290-4805-98A7-04339B8DEC71

Q39988564-0646DEFD-76AA-41E9-A4E2-8DCE98C34E96

Q39988564-07FF4B15-BDC7-4600-B39D-2A3564093451

Q39988564-0B316E8F-55A7-4AF9-9929-E23D825B154E

Q39988564-0E3131EA-6A18-425A-9882-34A67732F927

Q39988564-153F36E9-3F18-4113-B846-94D4559CB662

Q39988564-1948128F-5E04-4FBF-A388-B2EF73E547C7

Q39988564-1EFE9FF9-E953-4B82-8D4C-CEA32BC6708D

Q39988564-2301701B-5DC1-4E4C-910E-5E33126378FF

P304

Q39988564-80A001C4-87D9-470F-B94F-89C824935A8F

P31

Q39988564-B284CB88-07AA-422F-AB20-4309A93C8397

P356

Q39988564-D037E014-5C7B-4AAA-A117-8FADEDB0028F

P407

Q39988564-1C01E67A-6E13-48A5-96E1-92E67C956443

P478

Q39988564-BDC73BF8-E23B-401E-A965-9B7B023D24F3

P577

Q39988564-82B21D3C-FF0B-4456-9869-B7AB6A524290

P5875

Q39988564-839CB419-7D06-4C16-85D6-DA0E30FE0738

P698

Q39988564-57BF0A94-AB60-42CC-BBBE-D4EBEA8AD7C9

P932

Q39988564-4C3FF513-62E3-4BEC-AF9D-4394ED7B504A

P356

P1433

P1476

Incretin effects on β-cell function, replication, and mass: the human perspective.

@en

P2093

Alan J Garber

http://www.w3.org/2001/XMLSchema#string

P2860

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

P304

S258-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-S230

http://www.w3.org/2001/XMLSchema#string

P407

P478

34 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51082124

http://www.w3.org/2001/XMLSchema#string

P698

21525465

http://www.w3.org/2001/XMLSchema#string

P932

3632189

http://www.w3.org/2001/XMLSchema#string